09:42 AM EDT, 03/20/2024 (MT Newswires) -- Bristol-Myers Squibb Company ( BMY ) said Wednesday that a phase 3 trial evaluating the combination of Opdivo and Yervoy in patients with advanced hepatocellular carcinoma met its primary endpoint of improved overall survival.

The pharmaceutical giant said the combination therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with the investigator's choice of sorafenib or lenvatinib as a first-line treatment for hepatocellular carcinoma in patients who have not received prior systemic therapy.

The company also said the safety profile for the drug combination was consistent with previously reported data and was manageable with established protocols. No new safety signals were observed, the company added.